STX Insider Trading

Insider Ownership Percentage: 62.16%
Insider Buying (Last 12 Months): £23,000
Insider Selling (Last 12 Months): GBX 0

Shield Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Shield Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shield Therapeutics Share Price & Price History

Current Price: GBX 3.65
Price Change: Price Decrease of -0.05 (-1.35%)
As of 07/16/2025 11:57 AM ET

This chart shows the closing price history over time for STX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Shield Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2025Anders LundstromInsiderBuy575,000GBX 4£23,000
12/23/2022Greg MadisonInsiderSell466,395GBX 7£32,647.65
See Full Table

SEC Filings (Institutional Ownership Changes) for Shield Therapeutics (LON:STX)

11.92% of Shield Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Shield Therapeutics logo
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.
Read More on Shield Therapeutics

Today's Range

Now: GBX 3.65
Low: 3.50
High: 3.80

50 Day Range

MA: GBX 2.64
Low: 2.28
High: 3.75

52 Week Range

Now: GBX 3.65
Low: 1.55
High: 5.87

Volume

2,740,772 shs

Average Volume

1,962,332 shs

Market Capitalization

£36.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Who are the company insiders with the largest holdings of Shield Therapeutics?

Shield Therapeutics' top insider shareholders include:
  1. Anders Lundstrom (Insider)
Learn More about top insider investors at Shield Therapeutics.